This study investigates the efficacy and safety of plinabulin and docetaxel combination in patients with wild type NSCLC and large tumors requiring 2nd line therapy for advanced or metastatic disease after failing a platinum-containing regimen. The primary endpoint is overall survival (OS) with docetaxel alone as active comparator.